{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:03:32Z","timestamp":1782183812622,"version":"3.54.5"},"reference-count":111,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Stereotactic Body Radiotherapy (SBRT) has emerged as a pivotal treatment modality for early-stage non-small cell lung cancer (NSCLC), offering highly precise, high-dose radiation delivery. However, several clinical challenges remain, particularly in the treatment of central or ultracentral tumors, which are located near critical structures such as the heart, bronchi, and great vessels. The introduction of MRI-guided SBRT has significantly improved targeting precision, allowing for better assessment of tumor motion and adjacent organ structures. Additionally, SBRT has demonstrated efficacy in multifocal NSCLC, providing an effective option for patients with multiple primary tumors. Recent advances also highlight the role of SBRT in locally advanced NSCLC, where it is increasingly used as a complementary approach to concurrent chemotherapy or in cases where surgery is not feasible. Moreover, the combination of SBRT with immunotherapy has shown promising potential, enhancing tumor control and immunological responses. Furthermore, SBRTs application in SCLC is gaining momentum as a palliative and potentially curative option for selected patients. This narrative review explores these evolving clinical scenarios, the technical innovations supporting SBRT, and the integration of immunotherapy, providing an in-depth look at the new frontiers of SBRT in lung cancer treatment. Despite the challenges, the ongoing development of personalized approaches and technological advancements continues to push the boundaries of SBRTs clinical utility in lung cancer.<\/jats:p>","DOI":"10.3390\/jcm14144871","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T11:26:37Z","timestamp":1752233197000},"page":"4871","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lung Stereotactic Body Radiotherapy (SBRT): Challenging Scenarios and New Frontiers"],"prefix":"10.3390","volume":"14","author":[{"given":"Serena","family":"Badellino","sequence":"first","affiliation":[{"name":"Radiation Oncology, Department of Oncology, University of Turin, 10125 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0390-9511","authenticated-orcid":false,"given":"Francesco","family":"Cuccia","sequence":"additional","affiliation":[{"name":"Radiation Oncology, ARNAS Civico Hospital\u2014Palermo, 90145 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Galaverni","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Miele","sequence":"additional","affiliation":[{"name":"Operative Research Unit of Radiation Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9654-5587","authenticated-orcid":false,"given":"Matteo","family":"Sepulcri","sequence":"additional","affiliation":[{"name":"Radiotherapy, Veneto Institute of Oncology IOV\u2014IRCCS, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0992-9022","authenticated-orcid":false,"given":"Maria Alessia","family":"Zerella","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggero","family":"Spoto","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiosurgery, Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6196-5864","authenticated-orcid":false,"given":"Emanuele","family":"Al\u00ec","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, Azienda USL-Istituto di Ricovero e Cura a Carattere Scientifico Di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Olmetto","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Largo GA Brambilla, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5631-1575","authenticated-orcid":false,"given":"Luca","family":"Boldrini","sequence":"additional","affiliation":[{"name":"Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario A. Gemelli\u201dIRCCS, 00136 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-6779","authenticated-orcid":false,"given":"Antonio","family":"Pontoriero","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, Department of Biomedical, Dental and Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-7908","authenticated-orcid":false,"given":"Paolo","family":"Borghetti","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, ASST Spedali Civili and University of Brescia, P.le Spedali Civili, 1, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/OP.22.00475","article-title":"Stereotactic Body Radiotherapy for the Management of Early-Stage Non\u2013Small-Cell Lung Cancer: A Clinical Overview","volume":"19","author":"Buchberger","year":"2023","journal-title":"JCO Oncol. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.prro.2024.09.012","article-title":"Stereotactic Body Radiation Therapy for Primary Lung Cancer and Metastases: A Case-Based Discussion on Challenging Cases","volume":"15","author":"Sidiqi","year":"2025","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.athoracsur.2015.09.028","article-title":"Surgical Therapy for Bilateral Multiple Primary Lung Cancer","volume":"101","author":"Yang","year":"2016","journal-title":"Ann. Thorac. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jtcvs.2007.06.001","article-title":"Surgical treatment of synchronous multiple primary lung cancers: Experience of 92 patients","volume":"134","author":"Chang","year":"2007","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0022-5223(19)40289-4","article-title":"Multiple primary lung cancers","volume":"70","author":"Martini","year":"1975","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_6","first-page":"e369S","article-title":"Special treatment issues in non-small cell lung cancer-diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Benjamin","year":"2013","journal-title":"Chest"},{"key":"ref_7","unstructured":"Rami-Porta, R.A.H., Travis, W.D., and Rusch, V.W. (2017). AJCC Cancer Staging Manual, Springer International Publishing. [8th ed.]."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jtho.2016.01.025","article-title":"The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Detterbeck","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jtho.2016.01.024","article-title":"The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification","volume":"11","author":"Detterbeck","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"244S","DOI":"10.1378\/chest.123.1_suppl.244S","article-title":"Special treatment issues","volume":"123","author":"Detterbeck","year":"2003","journal-title":"Chest"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"290S","DOI":"10.1378\/chest.07-1382","article-title":"Special treatment issues in lung cancer-ACCP evidence-based clinical practice guidelines (2nd edition)","volume":"132","author":"Shen","year":"2007","journal-title":"Chest"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.21037\/jtd-23-1383","article-title":"Clinical and pathologic staging accuracy in patients with synchronous multiple primary lung cancers","volume":"16","author":"Tabrizi","year":"2024","journal-title":"J. Thorac. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1148\/radiol.2463062148","article-title":"Solitary pulmonary nodules: Meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy","volume":"246","author":"Cronin","year":"2008","journal-title":"Radiology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1007\/s00259-021-05624-5","article-title":"Joint EANM\/SNMMI\/ESTRO practice recommendations for the use of 2-[18F]FDG PET\/CT external beam radiation treatment planning in lung cancer V1.0","volume":"49","author":"Vaz","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","first-page":"1240","article-title":"Introduction to the 2015 World Health Organization Classification of Tumors of the lung, Pleura, Thymus, and heart","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung. Cancer."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cllc.2020.10.022","article-title":"Surgical Prognosis of Synchronous Multiple Primary Lung Cancer: Systematic Review and Meta-Analysis","volume":"22","author":"Nie","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Gao, S., Mao, Y., Mu, J., Xue, Q., Feng, X., and He, J. (2016). Surgical Outcomes of Synchronous Multiple Primary Non-Small Cell Lung Cancers. Sci. Rep., 6.","DOI":"10.1038\/srep23252"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"153376","DOI":"10.1016\/j.prp.2021.153376","article-title":"Correlation between spread through air spaces (STAS) and other clinicopathological parameters in lung cancer","volume":"220","author":"Aljamal","year":"2021","journal-title":"Pathol. Res. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Xie, H., Su, H., Zhu, E., Gu, C., Zhao, S., She, Y., Ren, Y., Xie, D., Zheng, H., and Wu, C. (2021). Morphological Subtypes of Tumor Spread Through Air Spaces in Non-Small Cell Lung Cancer: Prognostic Heterogeneity and Its Underlying Mechanism. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.608353"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"985","DOI":"10.21037\/atm-21-2256","article-title":"Integration of clinicopathological and mutational data offers insight into lung cancer with tumor spread through air spaces","volume":"9","author":"Tian","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Cao, L., Jia, M., Sun, P.L., and Gao, H. (2021). Histopathologic features from preoperative biopsies to predict spread through air spaces in early-stage lung adenocarcinoma: A retrospective study. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08648-0"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.athoracsur.2019.02.045","article-title":"Tumor Spread Through Air Spaces in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"108","author":"Chen","year":"2019","journal-title":"Ann. Thorac. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1016\/j.cllc.2019.05.012","article-title":"Tumor Spread through Air Spaces is a survival predictor in Non-small-cell Lung Cancer","volume":"20","author":"Wang","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s12253-019-00616-1","article-title":"Prognostic impact of Tumor Spread through Air spaces in Non-small Cell Lung cancers: A Meta-Analysis including 3564 patients","volume":"25","author":"Liu","year":"2019","journal-title":"Pathol. Oncol. Res. POR"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"12996","DOI":"10.1002\/cam4.5972","article-title":"Real-world comprehensive diagnosis and \u201cSurgery + X\u201d treatment strategy of early-stage synchronous multiple primary lung cancer","volume":"12","author":"Zhou","year":"2023","journal-title":"Cancer Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"478","DOI":"10.21037\/apm.2020.02.21","article-title":"Radiofrequency ablation of synchronous multiple primary lung cancer assisted by a magnetic navigation system: A case report","volume":"9","author":"Teng","year":"2020","journal-title":"Ann. Palliat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cllc.2018.10.010","article-title":"Stereotactic Body Radiotherapy for Early-Stage Multiple Primary Lung Cancers","volume":"20","author":"Nikitas","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/0284186X.2021.1892182","article-title":"Stereotactic body radiotherapy for synchronous early stage non-small cell lung cancer","volume":"60","author":"Steber","year":"2021","journal-title":"Acta Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3390\/curroncol29030140","article-title":"Repeated Multimodality Ablative Therapies for Oligorecurrent Pulmonary Metastatic Disease","volume":"29","author":"Macagno","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.21037\/tlcr.2018.08.15","article-title":"Stereotactic body radiotherapy as salvage treatment for recurrence of non-small cell lung cancer after prior surgery or radiotherapy","volume":"8","author":"Milano","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1016\/j.prro.2020.05.005","article-title":"Stereotactic body radiation therapy for salvage treatment of recurrent non-small cell lung cancer","volume":"10","author":"Kowalchuk","year":"2020","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101284","DOI":"10.1016\/j.adro.2023.101284","article-title":"Clinical and Dosimetric Risk Factors Associated with Radiation-Induced Lung Toxicities After Multiple Courses of Lung Stereotactic Body Radiation Therapy","volume":"9","author":"Li","year":"2023","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.radonc.2013.01.004","article-title":"Outcomes of stereotactic ablative radiotherapy for central lung tumours: A systematic review","volume":"106","author":"Senthi","year":"2013","journal-title":"Radiother. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/JTO.0000000000000453","article-title":"Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: What we have learned","volume":"10","author":"Chang","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2015.04.014","article-title":"Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors","volume":"89","author":"Chaudhuri","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jtho.2019.04.018","article-title":"Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review","volume":"14","author":"Chen","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology\/RTOG 0813 Trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-Trial-A Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated with Stereotactic Body Radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijrobp.2021.10.143","article-title":"Performing SBRT in the Fly-With-Caution Zone: Are We Heeding the Advice of Daedalus?","volume":"112","author":"Swaminath","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.ijrobp.2023.08.002","article-title":"Beyond the HILUS Trial: How Can We Improve the Safety of SABR for Ultracentral Thoracic Tumors?","volume":"117","author":"Safavi","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"107281","DOI":"10.1016\/j.lungcan.2023.107281","article-title":"Stereotactic body radiotherapy for Ultra-Central lung Tumors: A systematic review and Meta-Analysis and International Stereotactic Radiosurgery Society practice guidelines","volume":"182","author":"Yan","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jtho.2024.05.366","article-title":"Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results","volume":"19","author":"Levy","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijrobp.2024.03.050","article-title":"Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET)","volume":"120","author":"Giuliani","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_45","first-page":"100488","article-title":"Magnetic Resonance-Guided Stereotactic Body Radiation Therapy\/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions","volume":"4","author":"Sandoval","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijrobp.2020.02.025","article-title":"Clinical Outcomes of Stereotactic MR-Guided Adaptive Radiation Therapy for High-Risk Lung Tumors","volume":"107","author":"Finazzi","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2020.1760094","article-title":"Current radiotherapy techniques in NSCLC: Challenges and potential solutions","volume":"20","author":"Borghetti","year":"2020","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"103464","DOI":"10.1016\/j.esmoop.2024.103464","article-title":"Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: Interim analysis of overall survival from PACIFIC-R","volume":"9","author":"Filippi","year":"2024","journal-title":"ESMO Open"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"744956","DOI":"10.3389\/fonc.2021.744956","article-title":"A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer","volume":"11","author":"Bruni","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.cllc.2024.02.006","article-title":"Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients with Unresectable Stage III NSCLC: A Real-World Multicenter Study","volume":"25","author":"Park","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-Term Results of NRG Oncology RTOG 0617: Standard-Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1200\/JCO.2012.41.6677","article-title":"Hyperfractionated or accelerated radiotherapy in lung cancer: An individual patient data meta-analysis","volume":"30","author":"Mauguen","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.clon.2020.06.006","article-title":"Hypofractionated Accelerated Concurrent Chemoradiotherapy in Inoperable Stage III Non-small Cell Lung Cancer: SOCCAR. A Large Single-Centre Experience","volume":"32","author":"Patibandla","year":"2020","journal-title":"Clin. Oncol. (R Coll. Radiol.)"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.ejca.2014.07.009","article-title":"SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status","volume":"50","author":"Maguire","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2024.09.1437","article-title":"Accelerated Hypofractionated Radiotherapy for Locally Advanced NSCLC: A Systematic Review From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee","volume":"20","author":"Said","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jamaoncol.2021.3186","article-title":"Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II\/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial","volume":"7","author":"Iyengar","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Miljanic, M., Montalvo, S., Aliru, M., Song, T., Leon-Camarena, M., Innella, K., Vujovic, D., Komaki, R., and Iyengar, P. (2022). The Evolving Interplay of SBRT and the Immune System, along with Future Directions in the Field. Cancers, 14.","DOI":"10.3390\/cancers14184530"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"539","DOI":"10.7785\/tcrt.2012.500425","article-title":"Outcome study of cobalt based stereotactic body radiation therapy for patients with inoperable stage III non-small cell lung cancer","volume":"14","author":"Wang","year":"2015","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/1759-7714.13105","article-title":"Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer","volume":"10","author":"Cong","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13014-019-1317-x","article-title":"Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced nonsmall-cell lung cancer: Final results of a prospective phase-II trial with a long-term followup","volume":"14","author":"Parisi","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.ijrobp.2022.10.025","article-title":"STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial","volume":"115","author":"Arcidiacono","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/COC.0000000000000892","article-title":"Stereotactic Body Radiotherapy and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer: Single Arm Phase 2 Study","volume":"45","author":"Kubicek","year":"2022","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13014-023-02333-1","article-title":"Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: A retrospective study","volume":"18","author":"Jia","year":"2023","journal-title":"Radiat. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"110439","DOI":"10.1016\/j.radonc.2024.110439","article-title":"Stereotactic ablative radiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis","volume":"18","author":"Viani","year":"2024","journal-title":"Radiother. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Chi, A., Wen, S., Monga, M., Almubarak, M., He, X., Rojanasakul, Y., Tse, W., and Remick, S.C. (2016). Definitive upfront stereotactic ablative radiotherapy combined with image-guided, intensity modulated radiotherapy (IG-IMRT) or IGIMRT alone for locally advanced non-small cell lung cancer. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162453"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13014-018-1071-5","article-title":"Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies","volume":"13","author":"Kim","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.3390\/curroncol28050324","article-title":"Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)","volume":"28","author":"Monnet","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ijrobp.2024.02.020","article-title":"A Phase 2 Trial of Primary Tumor Stereotactic Body Radiation Therapy Boost Before Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer","volume":"120","author":"Williams","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"750","DOI":"10.21037\/jtd-23-304","article-title":"Phase I\/II study to evaluate consolidative hypofractionated radiation therapy for boosting the residual primary disease in combination with durvalumab after definitive chemoradiation therapy for stage III non-small cell lung cancer (NSCLC): Study protocol for a prospective trial","volume":"16","author":"Coutu","year":"2024","journal-title":"J. Thorac. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(24)00573-4","article-title":"Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: A multicentre, single-arm, phase 2 trial","volume":"26","author":"Heinzerling","year":"2025","journal-title":"Lancet. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijrobp.2008.01.054","article-title":"Once-Weekly, High-Dose Stereotactic Body Radiotherapy for Lung Cancer: 6-Year Analysis of 60 Early-Stage, 42 Locally Advanced, and 7 Metastatic Lung Cancers","volume":"72","author":"Salazar","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ijrobp.2012.11.011","article-title":"Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: A prospective study","volume":"85","author":"Feddock","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_73","first-page":"59","article-title":"Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB-IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities","volume":"5","author":"Karam","year":"2014","journal-title":"Lung. Cancer."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.ijrobp.2016.08.032","article-title":"Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study","volume":"96","author":"Hepel","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Kumar, S., Li, X., Feddock, J., Shearer, A.J., Hall, L., Shelton, B.J., Arnold, S., and McGarry, R.C. (2016). An Update on Results Regarding a Prospective Study of SBRT for Post-chemoradiation Residual Disease in Stage II\/III Non-small Cell Lung Cancer. Int. J. Radiat. Oncol. Biol. Phys., 96.","DOI":"10.1016\/j.ijrobp.2016.06.374"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jtho.2017.07.036","article-title":"Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study","volume":"12","author":"Higgins","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.radonc.2018.03.024","article-title":"Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial","volume":"127","author":"Doyen","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jamaoncol.2023.6033","article-title":"Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial","volume":"10","author":"Wu","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Crockett, C.B., Samson, P., Chuter, R., Dubec, M., Faivre-Finn, C., Green, O.L., Hackett, S.L., McDonald, F., Robinson, C., and Shiarli, A.M. (2021). Initial Clinical Experience of MR-Guided Radiotherapy for Non-Small Cell Lung Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.617681"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13014-022-02011-8","article-title":"MR-guided radiotherapy in node-positive non-small cell lung cancer and severely limited pulmonary reserve: A report proposing a new clinical pathway for the management of high-risk patients","volume":"17","author":"Eze","year":"2022","journal-title":"Radiat. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13014-023-02258-9","article-title":"Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced: The PUMA trial","volume":"18","author":"Regnery","year":"2023","journal-title":"Radiat. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.semradonc.2023.10.015","article-title":"The Future of MR-Guided Radiation Therapy","volume":"34","author":"Guckenberger","year":"2024","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13014-023-02244-1","article-title":"Ventilation and perfusion MRI at a 0.35 T MR-Linac: Feasibility and reproducibility study","volume":"18","author":"Klaar","year":"2023","journal-title":"Radiat. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"110468","DOI":"10.1016\/j.radonc.2024.110468","article-title":"MRI-based ventilation and perfusion imaging to predict radiation-induced pneumonitis in lung tumor patients at a 0.35T MR-Linac","volume":"199","author":"Klaar","year":"2024","journal-title":"Radiother. Oncol."},{"key":"ref_85","first-page":"16","article-title":"A review of the role of MRI in diagnosis and treatment of early stage lung cancer","volume":"24","author":"Sim","year":"2020","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_86","unstructured":"(2025, June 16). Small Cell Lung Cancer, Version 4.2025, NCCN Clinical Practice Guidelines in Oncology. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1462."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Simone CB2nd Bogart, J.A., Cabrera, A.R., Daly, M.E., DeNunzio, N.J., Detterbeck, F., Faivre-Finn, C., Gatschet, N., Gore, E., Jabbour, S.K., and Kruser, T.J. (2020). Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. Pract. Radiat. Oncol., 10, 158\u2013173.","DOI":"10.1016\/j.prro.2020.02.009"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/COC.0000000000000489","article-title":"Role of Stereotactic Body Radiation Therapy in Early Stage Small Cell Lung Cancer in the Era of Lung Cancer Screening: A Systematic Review","volume":"42","author":"Rathod","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"88","DOI":"10.21037\/tlcr.2018.11.03","article-title":"The optimal treatment approaches for stage I small cell lung cancer","volume":"8","author":"Moreno","year":"2019","journal-title":"Transl. Lung. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ijrobp.2016.10.041","article-title":"Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer","volume":"97","author":"Verma","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1016\/j.cllc.2018.03.017","article-title":"Comparing Treatment Strategies for Stage I Small-cell lung Cancer","volume":"19","author":"Paximadis","year":"2018","journal-title":"Clin. Lung. Cancer."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.lungcan.2021.07.007","article-title":"Stereotactic ablative radiotherapy in T1-2N0M0 small cell lung cancer: A systematic review and meta-analysis","volume":"160","author":"Safavi","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_93","first-page":"34","article-title":"The current role of surgery and SBRT in early stage of small cell lung cancer","volume":"7","author":"Guarino","year":"2021","journal-title":"J. Clin. Transl. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cllc.2023.11.005","article-title":"Stereotactic Ablative Radiotherapy in a Multicentric Series of Oligometastatic SCLC: The SAMOS Cohort","volume":"25","author":"Borghetti","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13073-019-0653-7","article-title":"Radiation therapy and anti-tumor immunity: Exposing immunogenic mutations to the immune system","volume":"11","author":"Lhuillier","year":"2019","journal-title":"Genome Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: A single-centre, randomised phase 2 trial","volume":"22","author":"Altorki","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"8435","DOI":"10.1038\/s41467-023-44195-x","article-title":"Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: Survival outcomes and molecular correlates of a randomized phase II trial","volume":"14","author":"Altorki","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S2213-2600(24)00215-7","article-title":"Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): A single-arm, single-centre, phase 2 trial","volume":"12","author":"Zhao","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jtho.2023.10.002","article-title":"Prospective Cohort Study to Compare Long-Term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a-b; \u226420 mm) NSCLC Treated by Stereotactic Body Radiation Therapy and Surgery","volume":"19","author":"Henschke","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: An open-label, randomised, phase 2 trial","volume":"402","author":"Chang","year":"2023","journal-title":"Lancet"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e001001","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: A randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: A pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","volume":"38","author":"Palma","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","article-title":"Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Meng, G., Liu, X., Ma, T., Lv, D., and Sun, G. (2022). Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0263629"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Rother, C., John, T., and Wong, A. (2024). Biomarkers for immunotherapy resistance in non-small cell lung cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1489977"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1200\/OP.24.00230","article-title":"How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer","volume":"20","author":"Malhotra","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s12094-023-03337-9","article-title":"Immunoradiotherapy for NSCLC: Mechanisms, clinical outcomes, and future directions","volume":"26","author":"Weishan","year":"2024","journal-title":"Clin. Transl. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/14\/4871\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:07:12Z","timestamp":1760033232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/14\/4871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":111,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["jcm14144871"],"URL":"https:\/\/doi.org\/10.3390\/jcm14144871","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]}}}